Abstract

Aim: YKL-40 is a novel biomarker that is associated with both acute and chronic inflammations. Elevated plasma concentrations of YKL-40 have been reported in patients with ischemic stroke. This study investigated the association of plasma YKL-40 concentrations at admission and short, long-term prognosis after ischemic stroke. Methods: This study is a prespecified biomarker sub-study of the third China National Stroke Registry (CNSR3), which is a prospective,national multi-center of 171 sites concerning consecutive patients of ischemic stroke and TIA within 7 days since onset with specimens collected at baseline. Plasma YKL-40 levels were detected by ELISA and patients were stratified into terciles according to Plasma YKL-40 concentrations. The multivariate Cox regression model was used to investigate the association of YKL-40 concentration and death and recurrence at 3 months, 6 months and 12 months after ischemic stroke, with potential confounders adjusted. Results: A total of 8013 first-ever ischemic stroke patients, with an average of 61.7±11.5 years, were included in this study. The YKL-40 concentrations of lower, middle and upper group were 30.36 ±8.53 mg/L, 64.89±13.49 mg/L, and 164.42±50.35 mg/L respectively. Higher YKL-40 concentration at admission was associated with combination events of death and recurrence, death as well as recurrence at 3-month, 6-month and 12-month since onset of ischemic stroke when compared with lower YKL-40 concentration. However, after adjusting for age, gender, smoking, drinking, hypertension, diabetes, low-density lipoprotein, and C-reactive protein, higher YKL-40 concentration at admission was just statistically associated with combination events and death, but not stroke recurrence at 3-month, 6-month and 12-month when compared with lower YKL-40 concentration (table 1). Conclusions: The elevated YKL-40 at admission was associated with short and long-term death, but not recurrence after ischemic stroke.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call